Hypertrophic Cardiomyopathy (HCM) is one of the most challenging diseases encountered in cardiology practice because of the diversity of its expression and unpredictable clinical course. In this symposium the evolving treatments for HCM symptoms will be discussed: medical treatment including disopyramide for obstruction, new surgical approaches to the mitral valve as adjuncts to myectomy, revised pathophysiologic understanding of SAM and other modalities such as alcohol septal ablation and AFib ablation. Implantable devices to prevent sudden death will be discussed in detail, focusing on risk stratification.
Current echocardiographic diagnosis and HCM subtypes will be covered, as well as stress echocardiography to provoke latent LVOT obstruction. Also, state of the art MRI in HCM will be covered, as well as genotype analysis for family screening. Pre-athletic participation screening will be covered. Installation of an automatic external defibrillator at every athletic playing field and practice session will be discussed. The participants will discuss investigational initiatives such as new pharmacologic therapy for mitigation of symptoms and slowing the development of phenotype as well as investigational interventional approaches to the mitral valve for treatment of obstruction in those with contraindications to myectomy.
12.5 AMA PRA Category 1 Credits™ - maximum
Venue: NYU Langone Medical Center
May 6-7, 2017
New York, New York 10016, United States